Condition: Photosensitivity · Microvesicle Particle · Sponsor: Wright State University
The purpose of this study is three-fold. First, researchers will assess whether subjects who have clinically abnormal reactions to sunlight (photosensitivity) have increased levels of microvesicle particles (MVP) following ultraviolet B (UVB) treatment to localized area of skin. Second, researchers will assess if topical application of the medicine imipramine will block UVB-induced MVP release. Third, researchers will assess if the topical cream will block UVB-induced increased erythema reactions (reddening of the skin).
This description comes directly from the study's public registry record.
Manager Clinical Research Operations · 937-245-7500 · pturesearch@wrightstatephysicians.org
Regulatory Specialist · 937-245-7500 · pturesearch@wrightstatephysicians.org
Always discuss trial participation with your own doctor first.
| Wright State Physicians | Fairborn, Ohio, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04520217